Updated cancer treatment framework offers new guidance on actionability and resistance biomarkers
Published . Updated .
This report does not map to a usual set of affected companies.
Directly affected
- No company is named in this report.
Indirectly affected
- No related companies are mapped for this report yet.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Updated cancer treatment framework offers new guidance on actionability and resistance biomarkers Medical Xpress
Source: Medical Xpress
This story
| Company | When | Move | Status |
|---|---|---|---|
| GLD | that day | -0.70% | final price |
| GLD | three days earlier | +2.33% | final price |
| GLD | five days earlier | +3.51% | final price |
| QQQ | that day | -0.02% | final price |
| QQQ | three days earlier | +1.80% | final price |
| QQQ | five days earlier | +0.75% | final price |
| SPY | that day | -0.48% | final price |
| SPY | three days earlier | +0.66% | final price |
| SPY | five days earlier | -0.09% | final price |
| TLT | that day | -0.53% | final price |
| TLT | three days earlier | -1.97% | final price |
| TLT | five days earlier | -2.07% | final price |
This story
12 out of 100
“Updated cancer treatment framework offers new guidance on actionability and resistance biomarkers” scores 12 out of 100. The score uses 1 sources.